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WHAT YOU NEED TO KNOW
• Data on bacterial prevalence and resistance trends are important in practice to inform local and national stewardship.
• Use evidence to choose first-, second-or thirdline antibiotics for bacterial infections in different tissues. Always aim for the lowest tier antimicrobial.
• When immediate therapy is needed, choose an appropriate antimicrobial based on likely susceptibility patterns.
• De-escalate antimicrobial therapy based on culture and antimicrobial susceptibility test results as soon as possible.
• Conduct clinical audit and benchmarking in your practice.
ANTIBIOTIC resistance is a very real threat to modern standards of human and veterinary healthcare. This is a one health problem -we share many antimicrobials, our bacteria are closely related, and the resistance genes are the same. All healthcare professionals therefore share a responsibility for antimicrobial stewardship to preserve the efficacy of these drugs for the future.
Monitoring resistance is a key part of stewardship. The paper by Teichmann-Knorrn and others 2 summarised on p 21 of this week's issue of Vet Record is therefore welcome and such studies are to be encouraged. Epidemiological data identifies resistance trends, which can inform local and national antimicrobial stewardship policies. This isn't just an academic exercise -awareness of national and local resistance patterns is directly relevant to clinical practice. However, we need to use this data wisely -for example, taken literally the abstract suggests that the critically important antimicrobials imipenem, nitrofurantoin, gentamicin and amoxicillin-clavulanate are the most appropriate drugs for feline urinary tract infections. However, only amoxicillin-clavulanate would be a first-line choice in feline urinary tract infections;
3-6 indiscriminate use of higher tier drugs could promote resistance to these highly important antimicrobials. 1, 5 To be fair, the authors later point out that imipenem should not be used in animals and emphasise caution in antimicrobial choice. can be confirmed using cytology and culture. Cytology can confirm the presence of infection (Fig  1) . Knowing the local and national prevalence of bacterial isolation helps us to identify the bacteria. However, this is gambling -we are playing the odds -and, wherever possible, bacterial culture and antimicrobial susceptibility testing should be performed.
Having identified the bacteria we need to select an appropriate antimicrobial. Ideally, we should wait for the culture results before starting therapy but there are circumstances where empirical therapy is appropriate or necessary (Box 1). Knowing antibiotic susceptibility patterns helps us select an appropriate drug. However, we are again gambling and this time we may err on the 'potent side' to minimise the risk of a treatment failure. This can lead to overuse of broad spectrum drugs.
Antimicrobials vary in their spectrum of activity (Fig 2) and are classified as first-, second-or thirdline drugs (Fig 3) . Always aim for the most narrow spectrum/lowest tier drug that is appropriate -these will be just as effective as more broad spectrum/ high tier drugs. Second-and third-line drugs should only be used where there is culture evidence to show that lower tier drugs are not appropriate and that other treatment options (eg, topical therapy) are not feasible. If immediate therapy is necessary we can use epidemiological data to select an appropriate antimicrobial. Where the data suggest that this should be a second-or third-line drug (as in the paper by Teichmann-Knorrn and others) starting with one of these can be appropriate. However, continued treatment should be justified by the culture resultswherever possible, treatment should be de-escalated to a lower tier drug.
Local and national patterns of bacterial isolation and antimicrobial susceptibility are also useful for benchmarking your practice. For example, do your urinary tract culture results reflect published findings? If not, this should prompt investigation and analysis. More immediate and practice specific benchmarking data can be obtained by engaging with software based data analysis programmes (eg, mySAVSNET AMR initiative 7 ).
In conclusion, monitoring of epidemiological trends for bacterial isolation and antimicrobial susceptibility is important for national antimicrobial stewardship policies, practice benchmarking, and guiding diagnosis and treatment choices. However, clinicians need to interpret the data carefully and in light of responsible antimicrobial use guidelines.
BOX 1: WHEN IS EMPIRICAL THERAPY APPROPRIATE OR NECESSARY?
• 
